Top

Published in:

27-05-2022 | Dementia | Review Article

Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update

Authors: Steve MacDonald, Ayushi Samir Shah, Babak Tousi

Published in: Drugs & Aging | Issue 7/2022

Abstract

The term Lewy body dementia refers to either of two related diagnoses: dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Clinical management of Lewy body dementia is challenging. The current treatment options focus on relieving symptoms; no disease-modifying therapies are available. There are currently no US Food and Drug Administration (FDA) approved drugs for the treatment of DLB, and there are only a few for PDD. Cholinesterase inhibitors are shown to be beneficial in improving cognitive symptoms in Lewy body dementia. Rivastigmine was approved by the FDA to treat PDD. Donepezil was approved in Japan as a treatment for DLB. Levodopa may provide modest benefit in treating motor symptoms and zonisamide in adjunct to low-dose levodopa helps with parkinsonism. Treatment of autonomic symptoms are based on symptomatic treatment with off-label agents. Our main objective in this article is to present an overview of the current pharmacological options available to treat the clinical features of DLB and PDD. When evaluating the existing management options for Lewy body dementia, it is difficult to fully separate PDD from DLB. However, we have attempted to identify whether the cited studies include patients with PDD and/or DLB. Moreover, we have provided an overview of the current drug pipeline in Lewy body dementia. All currently active trials are in phase I or II and most are focused on disease modification rather than symptomatic treatment. Phase II trial results for neflamapimod show promising results. Due to heterogeneity of symptoms and underlying pathophysiology, there is a need for new biomarker strategies and improved definitions of outcome measures for Lewy body dementia drug trials.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.CrossRef

Thomas AJ, Taylor JP, McKeith I, Bamford C, Burn D, Allan L, et al. Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. Int J Geriatr Psychiatry. 2017;32(12):1280–1304.CrossRef

O’Brien JT, Taylor J-P, Thomas A, Bamford C, Vale L, Hill S, et al. Improving the diagnosis and management of Lewy body dementia: the DIAMOND-Lewy research programme including pilot cluster RCT. Program Grants Appl Res. 2021;9(7):1–120.CrossRef

Taylor J-P, Pillai M. Current management strategies: the DIAMOND-Lewy toolkit. Alzheimer’s Dement [Internet]. 2021;17(Suppl.6):e052531. https://doi.org/10.1002/alz.052531.CrossRef

Vann Jones SA, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med [Internet]. 2014;44(4):673–83. https://pubmed.ncbi.nlm.nih.gov/23521899/. [cited 2021 Nov 14].

Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol [Internet]. 1998;57(4):334–7. https://pubmed.ncbi.nlm.nih.gov/9600226/. [cited 2021 Nov 14].

Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol [Internet]. 2008;115(4):427–36. https://pubmed.ncbi.nlm.nih.gov/18273624/. [cited 2021 Nov 14].

Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer’s disease. Neuroreport [Internet]. 1994;5(7):747–9. https://pubmed.ncbi.nlm.nih.gov/8018843/. [cited 2021 Nov 14].

Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain [Internet]. 1999;122 (Pt 8)(8):1449–68. https://pubmed.ncbi.nlm.nih.gov/10430831/. [cited 2021 Nov 14].

10.

Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology [Internet]. 2007;68(11):812–9. https://pubmed.ncbi.nlm.nih.gov/17353469/. [cited 2021 Nov 14].

11.

Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, et al. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer’s disease. J Alzheimers Dis [Internet]. 2011;24(2):383–91. https://pubmed.ncbi.nlm.nih.gov/21297274/. [cited 2021 Nov 14].

12.

Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D’Amore C, et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry [Internet]. 2008;64(10):850–5. https://pubmed.ncbi.nlm.nih.gov/18395699/. [cited 2021 Nov 14].

13.

McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol [Internet]. 2007;6(4):305–13. https://pubmed.ncbi.nlm.nih.gov/17362834/. [cited 2021 Nov 14].

14.

Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med [Internet]. 2013;14(8):754–62. https://pubmed.ncbi.nlm.nih.gov/23474058/. [cited 2021 Nov 14].

15.

Yoshita M, Arai H, Arai H, Arai T, Asada T, Fujishiro H, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One [Internet]. 2015;10(3). https://pubmed.ncbi.nlm.nih.gov/25793585/. [cited 2021 Nov 14].

16.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord [Internet]. 2015;30(12):1591–601. https://pubmed.ncbi.nlm.nih.gov/26474316/. [cited 2021 Nov 14].

17.

Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol [Internet]. 2017;13(4):217–31. https://pubmed.ncbi.nlm.nih.gov/28257128/. [cited 2021 Nov 14].

18.

Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord [Internet]. 2005;20(2):190–9. https://pubmed.ncbi.nlm.nih.gov/15551331/. [cited 2021 Nov 14].

19.

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord [Internet]. 2007;22(12):1689–707. https://pubmed.ncbi.nlm.nih.gov/17542011/. [cited 2021 Nov 14].

20.

Bradshaw J, Saling M, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer’s disease is qualitatively distinct. J Neurol Neurosurg Psychiatry [Internet]. 2004;75(3):382–7. https://pubmed.ncbi.nlm.nih.gov/14966152/. [cited 2021 Nov 14].

21.

Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O’Brien JT, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology [Internet]. 2000;54(8):1616–24. https://pubmed.ncbi.nlm.nih.gov/10762503/. [cited 2021 Nov 14].

22.

Grothe MJ, Schuster C, Bauer F, Prudlo J, Teipel SJ, Heinsen H. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia. J Neurol [Internet]. 2014;261(10):1939–48. https://pubmed.ncbi.nlm.nih.gov/25059393/. [cited 2021 Nov 14].

23.

McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6.CrossRef

24.

Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol [Internet]. 2012;72(1):41–52. https://pubmed.ncbi.nlm.nih.gov/22829268/. [cited 2021 Nov 14].

25.

Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4-014-0083–0 (eCollection 2015).CrossRef

26.

Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord [Internet]. 2007;23(6):401–5. https://pubmed.ncbi.nlm.nih.gov/17409748/. [cited 2021 Nov 14].

27.

Warre R, Thiele S, Talwar S, Kamal M, Johnston TH, Wang S, et al. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiol Dis [Internet]. 2011;41(3):591–604. https://pubmed.ncbi.nlm.nih.gov/20971190/. [cited 2021 Nov 14].

28.

Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol [Internet]. 2009;8(7):613–8. https://pubmed.ncbi.nlm.nih.gov/19520613/. [cited 2021 Nov 14].

29.

Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.CrossRef

30.

EIP. EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting [Internet accessed 2021 Nov 14]. 2020. https://www.eippharma.com/news/eip-pharma-announces-presentation-of-positive-clinical-trial-results-with-neflamapimod-at-the-13th-clinical-trials-in-alzheimers-disease-ctad-meeting/.

31.

Alam J, EIP Pharma Boston M. Clinical results with Novel Approaches that Reverses BFCN Dysfunction. J Prev Alzhiemer’s Dis. 2021;8(4):S9.

32.

Aarsland D, Ballard C, McKeith I, Perry RH, Larsen JP. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson’s disease. J Neuropsychiatry Clin Neurosci [Internet]. 2001;13(3):374–9. https://pubmed.ncbi.nlm.nih.gov/11514644/. [cited 2021 Nov 14].

33.

Burns A, O’Brien J, Group BAPDC, Auriacombe S, Ballard C, Broich K, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20(6):732–55.CrossRef

34.

Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, et al. Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord [Internet]. 2003;18(8):884–9. https://pubmed.ncbi.nlm.nih.gov/12889077/. [cited 2021 Nov 14].

35.

Molloy S, McKeith IG, O’Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry [Internet]. 2005;76(9):1200–3. https://pubmed.ncbi.nlm.nih.gov/16107351/. [cited 2021 Nov 14].

36.

Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248–50.CrossRef

37.

Sumitomo Dainippon Pharma Co. Sumitomo Dainippon Pharma Obtains Approval in Japan for TRERIEF, a therapeutic agent for Parkinson’s disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies [Internet]. 2018. https://www.ds-pharma.com/ir/news/2018/20180702.html. Accessed 4 Dec 2021.

38.

Murata M, Hasegawa K, Kanazawa I, Shirakura K, Kochi K, Shimazu R. Randomized placebo-controlled trial of zonisamide in patients with Parkinson’s disease. Neurol Clin Neurosci. 2016;4(1):10–15.

39.

Murata M, Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: a phase 3 randomized clinical trial. Park Relat Disord. 2020;76:91–97.CrossRef

40.

Dainippon Sumitomo Pharma Co. Parkinson’s disease drug “TRERIEF” obtained manufacturing and marketing approval [Internet]. 2009. https://www.ds-pharma.com/ir/news/2009/20090121.html.

41.

Seino M. Review of zonisamide development in Japan. Seizure. 2004.

42.

Tousi B, Leverenz JB. The application of zonisamide to patients suffering from dementia with Lewy bodies: emerging clinical data. Drug Des Devel Ther. 2021;15:1811–17.

43.

Shulman LM, Katzel LI, Ivey FM, Sorkin JD, Favors K, Anderson KE, et al. Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurol [Internet]. 2013;70(2):183–90. https://pubmed.ncbi.nlm.nih.gov/23128427/. [cited 2021 Nov 14].

44.

Uc EY, Doerschug KC, Magnotta V, Dawson JD, Thomsen TR, Kline JN, et al. Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology [Internet]. 2014;83(5):413–25. https://pubmed.ncbi.nlm.nih.gov/24991037/. [cited 2021 Nov 14].

45.

Song R, Grabowska W, Park M, Osypiuk K, Vergara-Diaz GP, Bonato P, et al. The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord [Internet]. 2017;41:3–13. https://pubmed.ncbi.nlm.nih.gov/28602515/. [cited 2021 Nov 14].

46.

Ballard C, Holmes C, McKeith I, Neill D, O’Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry [Internet]. 1999;156(7):1039–45. https://pubmed.ncbi.nlm.nih.gov/10401449/. [cited 2021 Nov 14].

47.

Leggett AN, Zarit S, Taylor A, Galvin JE. Stress and burden among caregivers of patients with Lewy body dementia. Gerontologist. 2011;51(1):76–85.CrossRef

48.

Jellinger KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies. J Neural Transm [Internet]. 2018;125(4):615–50. https://pubmed.ncbi.nlm.nih.gov/29222591/. [cited 2021 Nov 14].

49.

Ballard CG, O’Brien JT, Swann AG, Thompson P, Neill D, McKeith IG. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer’s disease: persistence and new cases over 1 year of follow-up. J Clin Psychiatry [Internet]. 2001;62(1):46–9. https://pubmed.ncbi.nlm.nih.gov/11235928/. [cited 2021 Nov 14].

50.

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690–705.CrossRef

51.

Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008;46(1):101–6.CrossRef

52.

Chiu PY, Wang CW, Tsai CT, Li SH, Lin CL, Lai TJ. Depression in dementia with Lewy bodies: A comparison with Alzheimer’s disease. PLoS One [Internet]. 2017;12(6). https://pubmed.ncbi.nlm.nih.gov/28617831/. [cited 2021 Nov 14].

53.

Aarsland D, Perry R, Larsen JP, McKeith IG, O’Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry [Internet]. 2005;66(5):633–7. https://pubmed.ncbi.nlm.nih.gov/15889951/. [cited 2021 Nov 14].

54.

Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(3):549–53.CrossRef

55.

Kurlan R, Cummings J, Raman R, Thal L, Group ADCS. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–63.CrossRef

56.

Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord [Internet]. 2002];13(2):67–73. https://pubmed.ncbi.nlm.nih.gov/11844887/. [cited 2021 Nov 14.

57.

Pollak P, Tison F, Rascol O, Destée A, Péré JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry [Internet]. 2004;75(5):689–95. https://pubmed.ncbi.nlm.nih.gov/15090561/. [cited 2021 Nov 14].

58.

Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103–11.CrossRef

59.

Chu CS, Yang FC, Tseng PT, Stubbs B, Dag A, Carvalho AF, et al. Treatment efficacy and acceptabilityof pharmacotherapies for dementia with Lewy bodies: a systematic review and network meta-analysis. Arch Gerontol Geriatr [Internet]. 2021;96. https://pubmed.ncbi.nlm.nih.gov/34256210/. [cited 2021 Nov 14].

60.

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2014;383(9916):533–40.CrossRef

61.

Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer DL, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med [Internet]. 2021];385(4):309–19. https://pubmed.ncbi.nlm.nih.gov/34289275/. [cited 2021 Nov 14.

62.

Acadia Pharmaceuticals Receives Complete Response Letter from US FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis | Acadia Pharmaceuticals Inc. [Internet]. [Accessed 2021 Nov 14]. https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-receives-complete-response-letter-us-fda.

63.

Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A receptor inverse agonist as a treatment for Parkinson’s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimer’s Dis. 2016;50(3):733–40.CrossRef

64.

Horn S, Richardson H, Xie SX, Weintraub D, Dahodwala N. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson’s disease and dementia with Lewy bodies. Park Relat Disord. 2019;69:119–24.CrossRef

65.

Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19:157–69.CrossRef

66.

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019;34:180–98.CrossRef

67.

Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord [Internet]. 2010;24(4):360–4. https://pubmed.ncbi.nlm.nih.gov/20625270/. [cited 2021 Nov 14].

68.

Arrigoni E, Chen MC, Fuller PM. The anatomical, cellular and synaptic basis of motor atonia during rapid eye movement sleep. J Physiol. 2016;594:5391–414.CrossRef

69.

Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013;9(2):189–98.CrossRef

70.

Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology [Internet]. 2009;72(15):1296–300. https://pubmed.ncbi.nlm.nih.gov/19109537/. [cited 2021 Nov 14].

71.

Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med [Internet]. 2013;14(8):744–8. https://pubmed.ncbi.nlm.nih.gov/23347909/. [cited 2021 Nov 14].

72.

Neikrug AB, Ancoli-Israel S. Diagnostic tools for REM sleep behavior disorder. Sleep Med Rev [Internet]. 2012;16(5):415–29. https://pubmed.ncbi.nlm.nih.gov/22169258/. [cited 2021 Nov 14].

73.

Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, et al. Sleep and circadian rhythm regulation in early parkinson disease. JAMA Neurol. 2014;71(5):589–95.CrossRef

74.

McCarter SJ, Boswell CL, St. Louis EK, Dueffert LG, Slocumb N, Boeve BF, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med [Internet]. 2013;14(3):237–42. https://pubmed.ncbi.nlm.nih.gov/23352028/. [cited 2021 Nov 14].

75.

McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19–26.CrossRef

76.

Schenck CH, Mahowald MW. Polysomnographie, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients. Cleve Clin J Med [Internet]. 1990;57(1 suppl 1):S-9. https://www.ccjm.org/content/57/1_suppl_1/S-9. [cited 2021 Nov 14].

77.

Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain [Internet]. 2000;123 (Pt 2)(2):331–9. https://pubmed.ncbi.nlm.nih.gov/10648440/. [cited 2021 Nov 14].

78.

Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med [Internet]. 1996;100(3):333–7. https://pubmed.ncbi.nlm.nih.gov/8629680/. [cited 2021 Nov 14].

79.

Di Giacopo R, Fasano A, Quaranta D, Marca G Della, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord [Internet]. 2012;27(4):559–61. https://pubmed.ncbi.nlm.nih.gov/22290743/. [cited 2021 Nov 14].

80.

Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology [Internet]. 2000;55(6):870–1. https://pubmed.ncbi.nlm.nih.gov/10994012/. [cited 2021 Nov 14].

81.

Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology [Internet]. 2006;67(5):742–7. https://pubmed.ncbi.nlm.nih.gov/16966533/. [cited 2021 Nov 14].

82.

Mendoza-Velásquez JJ, Flores-Vázquez JF, Barrón-Velázquez E, Sosa-Ortiz AL, Illigens BMW, Siepmann T. Autonomic Dysfunction in α-Synucleinopathies. Front Neurol [Internet]. 2019;10(APR). https://pubmed.ncbi.nlm.nih.gov/31031694/. [cited 2021 Nov 14].

83.

Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol [Internet]. 2013;9(1):13–24. https://pubmed.ncbi.nlm.nih.gov/23183883/. [cited 2021 Nov 14].

84.

Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry [Internet]. 2001;71(5):583–8. https://pubmed.ncbi.nlm.nih.gov/11606666/. [cited 2021 Nov 14].

85.

Joseph A, Wanono R, Flamant M, Vidal-Petiot E. Orthostatic hypotension: a review. Nephrol Ther [Internet]. 2017;13 Suppl 1:S55–67. https://pubmed.ncbi.nlm.nih.gov/28577744/. [cited 2021 Nov 14].

86.

Horimoto Y, Matsumoto M, Akatsu H, Ikari H, Kojima K, Yamamoto T, et al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol [Internet]. 2003;250(5):530–3. https://pubmed.ncbi.nlm.nih.gov/12736730/. [cited 2021 Nov 14].

87.

Bengtsson-Lindberg M, Larsson V, Minthon L, Wattmo C, Londos E. Lack of orthostatic symptoms in dementia patients with orthostatic hypotension. Clin Auton Res [Internet]. 2015;25(2):87–94. https://pubmed.ncbi.nlm.nih.gov/24743866/. [cited 2021 Nov 14].

88.

Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord [Internet]. 2018;33(3):372–90. https://pubmed.ncbi.nlm.nih.gov/29508455/. [cited 2021 Nov 14].

89.

Tateno F, Sakakibara R, Ogata T, Kishi M, Tsuyusaki Y, Takahashi O, et al. Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord [Internet]. 2015;30(3):411–5. https://pubmed.ncbi.nlm.nih.gov/25356960/. [cited 2021 Nov 14].

90.

Peyronnet B, Vurture G, Palma JA, Malacarne DR, Feigin A, Sussman RD, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord [Internet]. 2018;57:22–6. https://pubmed.ncbi.nlm.nih.gov/30037689/. [cited 2021 Nov 14].

91.

Kalf JG, De Swart BJM, Borm GF, Bloem BR, Munneke M. Prevalence and definition of drooling in Parkinson’s disease: a systematic review. J Neurol [Internet]. 2009;256(9):1391–6. https://pubmed.ncbi.nlm.nih.gov/19288042/. [cited 2021 Nov 14].

92.

Arbouw MEL, Movig KLL, Koopmann M, Poels PJE, Guchelaar HJ, Egberts TCG, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology [Internet]. 2010;74(15):1203–7. https://pubmed.ncbi.nlm.nih.gov/20385892/. [cited 2021 Nov 14].

93.

Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord [Internet]. 2011;26 Suppl 3(0 3). https://pubmed.ncbi.nlm.nih.gov/22021174/. [cited 2021 Nov 14].

94.

Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, et al. Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol [Internet]. 2015;22(1):37–43. https://pubmed.ncbi.nlm.nih.gov/23607783/. [cited 2021 Nov 14].

95.

Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson’s disease with dementia. PLoS One [Internet]. 2012;7(10). https://pubmed.ncbi.nlm.nih.gov/23049679/. [cited 2021 Nov 14].

96.

Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EMM. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord [Internet]. 1997;12(6):946–51. https://pubmed.ncbi.nlm.nih.gov/9399219/. [cited 2021 Nov 14].

97.

Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord [Internet]. 2007;22(9):1239–44. https://pubmed.ncbi.nlm.nih.gov/17566120/. [cited 2021 Nov 14].

98.

Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease. Neurology. 2016;87(12):1274–80.CrossRef

99.

Freitas ME, Alqaraawi A, Lang AE, Liu LWC. Linaclotide and prucalopride for management of constipation in patients with parkinsonism. Mov Disord Clin Pract. 2018;5(2):218–20.CrossRef

100.

Eisai. ARICEPT^® approved in japan as treatment for dementia with Lewy bodies [Internet]. 2014. https://www.eisai.com/news/news201452.html. [cited 2022 Mar 30].

101.

Lang FM, Kwon DY, Aarsland D, Boeve B, Tousi B, Harnett M, et al. An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). Alzheimers Dement (N Y). 2021;7(1):e12171.

102.

Hebron M, Moussa CEH. Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration. Neural Regener Res. 2015;10:1767–9.CrossRef

103.

Hebron ML, Lonskaya I, Moussa CEH. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson’s disease models. Hum Mol Genet. 2013;22(16):3315–28.CrossRef

104.

Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, et al. C-Abl phosphorylates α-synuclein and regulates its degradation: Implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease. Hum Mol Genet. 2014;23(11):2858–79.CrossRef

105.

Merchant K, Simuni T, Fiske B, Coffey C, Matthews H, Wyse R, et al. Pharmacokinetics and biomarker changes in NILO-PD, a phase 2A study of nilotinib in patients with moderate to advance Parkinson’s disease (4418). Neurology. 2020;94(15 Supplement).

106.

Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, et al. Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease. Ann Neurol. 2020;88(1):183–94.CrossRef

107.

Lonskaya I, Hebron ML, Selby ST, Turner RS, Moussa CEH. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models. Neuroscience. 2015;304:316–27.CrossRef

108.

Mahdavi K, Jordan S, Barrows H, Pravdic M, Habelhah B, Evans N, et al. Treatment of dementia with bosutinib: an open-label study of a tyrosine kinase inhibitor. Neurol Clin Pract. 2021;11(3):e294–e302.CrossRef

109.

Ando M, Ishikawa Y, Horie K, Mochizuki T, Yamamoto M, Watanabe N, et al. P3‐062: effect of repeated administration of E2027, a novel phosphodiesterase‐9 inhibitor, on cyclic GMP levels in rat cerebrospinal fluid. Alzheimer’s Dement. 2018;14(7S_Part_20).

110.

Höllerhage M, Moebius C, Melms J, Chiu WH, Goebel JN, Chakroun T, et al. Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep. 2017;7(1):11469.

111.

Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, et al. Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases. J Clin Investig. 2019;129(10):4539–4549.CrossRef

112.

Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottegård A. Association of glycolysis-enhancing α-1 blockers with risk of developing Parkinson disease. JAMA Neurol. 2021;78(4):407–413.CrossRef

113.

Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11(11):986–98.CrossRef

114.

Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, et al. Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2019;19(1):20.

115.

Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, et al. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2019;5:20–26.CrossRef

116.

Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimer’s Dement. 2021;17(8)1365–1382.

117.

Arotcarena M-L, Teil M, Dehay B. Autophagy in synucleinopathy: the overwhelmed and defective machinery. Cells. 2019;8(6):565.CrossRef

118.

Barth AL, Schneider JS, Johnston TH, Hill MP, Brotchie JM, Moskal JR, et al. NYX-458 improves cognitive performance in a primate Parkinson’s disease model. Mov Disord. 2020;35(4):640–9.CrossRef

119.

CuraSen. Safety, Tolerability and cerebral blood flow after single doses of the Β2-agonist, Clebbuterol, in patients with mild cognitive impairment or Parkinson’s disease. [Internet]. 2021 [cited 2022 Mar 30]. https://www.curasen.com/curasen-therapeutics-presents-phase-1b-clinical-data-with-cst-103-demonstrating-significant-increases-in-cerebral-blood-flow-in-patients-with-mild-cognitive-impairment-or-parkinsons-disease/.

120.

Lodeweyckx T, De hoon J, Van Laere K, Koole M, Vandenberghe W, Bishop C, et al. Abstract: Posters: 14th Clinical Trials on Alzheimer’s Disease (CTAD) November 9-12, 2021. J Prev Alzheimer’s Dis [Internet]. 2021;8(S1):S73–170. Available from: https://pubmed.ncbi.nlm.nih.gov/34773456

121.

ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine, (US). A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders (CLIN-011) [Internet]. NCT04739423. 2021 [Accessed 2022 Dec 3]. https://clinicaltrials.gov/ct2/show/NCT04739423?term=cst-103&cond=Lewy+Body+Disease&draw=2&rank=1.

122.

Takeuchi D, Sato N, Shimamura M, Kurinami H, Takeda S, Shinohara M, et al. Alleviation of Aβ-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008;15(8):561–71.CrossRef

123.

Moebius H, Hua X, Church K, Walker W, L’hostis P, Danjou P, et al. Phase 1 study of NDX-1017: safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and dementia patients. J Prev Alzheimer’s Dis. 2019;6, S22.

Title: Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update
Authors: Steve MacDonald
Ayushi Samir Shah
Babak Tousi
Publication date: 27-05-2022
Publisher: Springer International Publishing
Keywords: Dementia
Parkinson's Disease
Dementia
Zonisamide
Published in: Drugs & Aging / Issue 7/2022
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-022-00939-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2022

Relationship Amongst Vitamin K Status, Vitamin K Antagonist Use and Osteoarthritis: A Review

Antihypertensive Drugs and Risk of Bone Fractures

Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents

Potentially Inappropriate Medications Pre- and Post-Diagnosis of Major Neurocognitive Disorders Among Older People in Sweden: A Register-Based, 6-Year Longitudinal Study

Pharmacotherapy for Spine-Related Pain in Older Adults

Incident Functional Limitations Among Community-Dwelling Adults Using Opioids: A Retrospective Cohort Study Using a Propensity Analysis with the Health and Retirement Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials